Sanofi: Difficult to increase value through molecular route
According to the management of the French company’s diabetes division the coming decade will not necessarily be driven by molecular innovation. Find out more about where Sanofi sees innovation headed in the future.
Berlin: The next ten years might not be driven by molecular innovation, instead we might see a paradigm shift in terms of how patients are handled, according to medical director of Sanofi’s diabetes division, Ricardo Perfetti.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Sanofi: We will definitely make an objection
For abonnenter
